Bruker Corporation (ETR:BKD)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.13B +70.2% |
| Revenue (ttm) | 3.06B +1.7% |
| Net Income | -93.57M |
| EPS | -0.62 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 26.07 |
| Dividend | 0.17 (0.32%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Volume | n/a |
| Open | 54.35 |
| Previous Close | 53.67 |
| Day's Range | 53.78 - 54.35 |
| 52-Week Range | 44.73 - 58.59 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
News
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolu...
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows fo...
Bruker Transcript: Bank of America Global Healthcare Conference
Order growth in China, biopharma, and semi-metrology drove strong bookings, while U.S. academic funding remained weak but is showing signs of improvement for 2027. AI is expected to be a major growth driver for advanced research tools, and ongoing cost-saving programs and recurring revenue expansion are set to support margin growth.
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
BERKELEY, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Re...
Bruker Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted a strategic focus on deep tech, diagnostics, and advanced multi-omics tools, with AI and automation poised to drive significant growth from 2027 onward. Strong order growth in biopharma, semiconductors, and China, along with innovation in diagnostics and spatial biology, positions the business for robust long-term performance.
Bruker Transcript: Wells Fargo 21st Annual Healthcare Conference
Reorganization and acquisitions are integrating NMR, mass spectrometry, and humanized systems for advanced drug discovery and AI. Strong financials show robust order growth in China and tech markets, though revenue is delayed by complex contracts. Proteomics, AI automation, and new partnerships drive leadership in biological analysis.
Bruker Corporation to Present at Upcoming Investor Conferences
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual Healt...
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luva...
Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories
BOSTON--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technol...
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development
LEIDEN, The Netherlands--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced...
Bruker Earnings Call Transcript: Q2 2026
Q2 2026 saw a return to organic revenue growth, significant margin and EPS expansion, and robust order growth in deep tech and biopharma. FY 2026 guidance remains unchanged, with strong Q4 performance expected, driven by semiconductor and energy research demand.
Bruker Earnings release: Q2 2026
Bruker released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bruker Slides: Q2 2026
Bruker has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bruker Quarterly report: Q2 2026
Bruker has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bruker Reports Second Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and six months ended June 30, 2026. Frank H. Laukien, Bruker's Pres...
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 20...
Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
BREMEN, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.DISQVER® enables m...
Bruker Transcript: Jefferies Global Healthcare Conference 2026
Strong order growth in Q1 was led by semiconductor and international academic/government markets, while U.S. funding delays persist. Biopharma and security segments are robust outside the U.S., and cost-saving actions are driving margin improvements, with double-digit EPS growth expected through 2027.
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and ...
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fue...
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultr...
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at...
Bruker Transcript: AGM 2026
The meeting confirmed a quorum, elected three directors through 2029, approved 2025 executive compensation, and ratified the appointment of independent auditors for 2026. Stockholders were invited to submit questions before adjournment.
Bruker Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong bookings in AI-driven and security segments, despite U.S. academic and currency headwinds. Guidance for FY2026 is reaffirmed, with margin expansion and EPS growth driven by cost savings and innovation momentum.